Efficacy and safety of adding evogliptin versus sitagliptin for metformin-treated patients with type 2 diabetes: A 24-week randomized, controlled trial with open label extension.
Sung Woo ParkCheol-Young ParkDong-Min HwangKyung Ah HanChang Beom LeeChoon Hee ChungKun-Ho YoonJi-Oh MokKyong Soo ParkSung-Woo ParkPublished in: Diabetes, obesity & metabolism (2017)
Evogliptin 5 mg added to metformin therapy effectively improved glycaemic control and was non-inferior to sitagliptin and well tolerated in patients with type 2 diabetes mellitus that was inadequately controlled by metformin alone.